Efficacy and toxicity of SEAM (semustine, etoposide, cytarabine, and melphalan) conditioning regimen followed by autologous stem cell transplantation in lymphoma

References

• Philip T, Armitage JO, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-hodgkin's lymphoma. N Engl J Med. 1987;316(24):1493–1498.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. The Lancet. 2002;359(9323):2065–2071.
   PubMed Web of Science ®Google Scholar
• Gribben JG, Linch DC, Singer CR, et al. Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood. 1989;73(1):340–344.
   PubMed Web of Science ®Google Scholar
• Darrington DL, Vose JM, Anderson JR, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol. 1994;12(12):2527–2534.
   PubMed Web of Science ®Google Scholar
• Montoto S, Canals C, Rohatiner AZ, et al. Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia. 2007;21(11):2324–2331.
   PubMed Web of Science ®Google Scholar
• Mills W, Chopra R, McMillan A, et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol. 1995;13(3):588–595.
   PubMed Web of Science ®Google Scholar
• Caballero MD, Rubio V, Rifon J, et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 1997;20(6):451–458.
   PubMed Web of Science ®Google Scholar
• Mounier N, Gisselbrecht C. Conditioning regimens before transplantation in patients with aggressive non-Hodgkin's lymphoma.
   Google Scholar
• Ann Oncol. 1998;9(Suppl 1):S15–S21.
   PubMedGoogle Scholar
• Gu B, Zhang X, Chen G, et al. Efficacy of haploidentical hematopoietic stem cell transplantation compared to HLA-matched transplantation for primary refractory acute myeloid leukemia. Ann Hematol 2018.
   Google Scholar
• Zhang XH, Huang XJ, Liu KY, et al. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma. Chin Med J. 2007;120(6):463–468.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–586.
   PubMed Web of Science ®Google Scholar
• Sharma A, Kayal S, Iqbal S, et al. Comparison of BEAM vs. LEAM regimen in autologous transplant for lymphoma at AIIMS. SpringerPlus. 2013;2:489.
   PubMed Web of Science ®Google Scholar
• Kim JE, Lee DH, Yoo C, et al. BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity. Leuk Res 2011;35(2):183–187.
   PubMed Web of Science ®Google Scholar
• Visani G, Malerba L, Stefani PM, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood. 2011;118(12):3419–3425.
   PubMed Web of Science ®Google Scholar
• Stuart MJ, Chao NS, Horning SJ, et al. Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease. Biol Blood Marrow Transplant. 2001;7(10):552–560.
   PubMed Web of Science ®Google Scholar
• Olivieri J, Mosna F, Pelosini M, et al. A comparison of the conditioning regimens BEAM and FEAM for autologous hematopoietic stem cell transplantation in lymphoma: An observational study on 1038 patients from fondazione italiana linfomi. Biol Blood Marrow Transplant. 2018;24(9):1814–1822.
   PubMed Web of Science ®Google Scholar
• Wheeler GP. Studies related to the mechanisms of action of cytotoxic alkylating agents: a review. Cancer Res 1962;22:651–688.
   PubMed Web of Science ®Google Scholar
• Jo JC, Kang BW, Jang G, et al. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol 2008;87(1):43–48.
   PubMed Web of Science ®Google Scholar
• Shi Y, Liu P, Zhou S, et al. Comparison of CBV, BEAM and BEAC high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non-hodgkin lymphoma: Efficacy and toxicity. Asia Pac J Clin Oncol. 2017;13(5):e423–e429.
   PubMed Web of Science ®Google Scholar
• Khayat D, Lokiec F, Bizzari JP, et al. Phase I clinical study of the new amino acid-linked nitrosourea, S 10036, administered on a weekly schedule. Cancer Res 1987;47(24 Pt 1):6782–6785.
   PubMed Web of Science ®Google Scholar
• Young RC, Walker MD, Canellos GP, et al. Initial clinical trials with methyl-CCNU 1-(2-chlorethyl)-3-(4-methyl cyclohexyl)-1-nitrosourea (MeCCNU). Cancer. 1973;31(5):1164–1169.
   PubMed Web of Science ®Google Scholar
• Bouffet E, Khelfaoui F, Philip I, et al. High-dose carmustine for high-grade gliomas in childhood. Cancer Chemother Pharmacol 1997;39(4):376–379.
   PubMed Web of Science ®Google Scholar
• Khattry N, Gupta A, Jain R, et al. LACE versus BEAM conditioning in relapsed and refractory lymphoma transplant: retrospective multicenter analysis of toxicity and efficacy. Int J Hematol 2016;103(3):292–298.
   PubMed Web of Science ®Google Scholar
• Marchesi F, Capria S, Giannarelli D, et al. BEAM vs FEAM high-dose chemotherapy: retrospective study in lymphoma patients undergoing autologous stem cell transplant. Bone Marrow Transplant 2018;53(8):1051–1054.
   PubMed Web of Science ®Google Scholar
• Wang EH, Chen YA, Corringham S, et al. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma. Bone Marrow Transplant 2004;34(7):581–587.
   PubMed Web of Science ®Google Scholar
• Zaucha R, Gooley T, Holmberg L, et al. High-dose chemotherapy with BEAM or busulphan/melphalan and thiotepa followed by hematopoietic cell transplantation in malignant lymphoma. Leuk Lymphoma. 2008;49(10):1899–1906.
   PubMed Web of Science ®Google Scholar
• Chen YB, Lane AA, Logan B, et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015;21(6):1046–1053.
   PubMed Web of Science ®Google Scholar
• Weaver CH, Appelbaum FR, Petersen FB, et al. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy. J Clin Oncol. 1993;11(7):1329–1335.
   PubMed Web of Science ®Google Scholar
• Alessandrino EP, Bernasconi P, Colombo A, et al. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. Bone Marrow Transplant 2000;25(3):309–313.
   PubMed Web of Science ®Google Scholar
• Clark JG, Hansen JA, Hertz MI, et al. NHLBI workshop summary. idiopathic pneumonia syndrome after bone marrow transplantation. Am Rev Respir Dis 1993;147(6 Pt 1):1601–1606.
   PubMed Web of Science ®Google Scholar
• Demirer T, Weaver CH, Buckner CD, et al. High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy. J Clin Oncol. 1995;13(3):596–602.
   PubMed Web of Science ®Google Scholar
• Panoskaltsis-Mortari A, Griese M, Madtes DK, et al. An official American thoracic society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome. Am J Respir Crit Care Med 2011;183(9):1262–1279.
   PubMed Web of Science ®Google Scholar
• Todd NW, Peters WP, Ost AH, et al. Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation. Am Rev Respir Dis. 1993;147(5):1264–1270.
   PubMedGoogle Scholar
• Robinson SP, Boumendil A, Finel H, et al. High-dose therapy with BEAC conditioning compared to BEAM conditioning prior to autologous stem cell transplantation for non-hodgkin lymphoma: no differences in toxicity or outcome. A matched-control study of the EBMT-lymphoma working party. Bone Marrow Transplant 2018;53(12):1553–1559.
   PubMed Web of Science ®Google Scholar
• Kothari J, Foley M, Peggs KS, et al. A retrospective comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma: LEAM and BEAM. Bone Marrow Transplant 2016;51(10):1397–1399.
   PubMed Web of Science ®Google Scholar
• Huang H, Zhang L, Jiang Y, et al. Modified BuCy is an alternative conditioning regimen for lymphoma patients undergoing autologous stem cell transplantation. Ann Hematol 2019;98(5):1259–1266.
   PubMed Web of Science ®Google Scholar
• Ko OB, Jang G, Kim S, et al. Autologous stem cell transplantation for diffuse large B-cell lymphoma with residual extranodal involvement. Korean J Intern Med 2008;23(4):182–190.
   PubMedGoogle Scholar
• Sohn BS, Park I, Kim EK, et al. Comparison of clinical outcome after autologous stem cell transplantation between patients with peripheral T-cell lymphomas and diffuse large B-cell lymphoma. Bone Marrow Transplant 2009;44(5):287–293.
   PubMed Web of Science ®Google Scholar
• Qian F, Fan W, Wei X, et al. Prognostic factors of lymphoma patients after autologous stem cell transplantation. Ann Transplant 2015;20:225–232.
   PubMed Web of Science ®Google Scholar
• Yang DH, Kim WS, Kim SJ, et al. Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome. Biol Blood Marrow Transplant. 2009;15(1):118–125.
   PubMed Web of Science ®Google Scholar
• Hosing C, Saliba RM, Okoroji GJ, et al. High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-hodgkin's lymphoma in patients >65 years of age. Ann Oncol. 2008;19(6):1166–1171.
   PubMed Web of Science ®Google Scholar
• Pham RN, Gooley TA, Keeney GE, et al. The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphoma. Bone Marrow Transplant. 2007;40(11):1039–1044.
   PubMed Web of Science ®Google Scholar